Drug
Tegavivint clinical trials
Also written BC2059.
- studies test it
- 8
- open now
- 6
- in phase 3
- 0
- first study started
- 2018
Keep track of what changes. Save the tegavivint studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- BC2059
- 15
Studies by the year they started
8 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 7
M.D. Anderson Cancer Center (1) · Iterion Therapeutics (1) · University of Texas Southwestern Medical Center (1) · Emory University (1) · Ohio State University Comprehensive Cancer Center (1) · Children's Oncology Group (1) · HonorHealth Research Institute (1) · Lapo Alinari (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tegavivint is read from its arms, and is right about nine times in ten.
Testing it · 8
- Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaRecruitingPhase 1Emory UniversityNCT07144254Written as Tegavivint
- Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingPhase 1/2University of Texas Southwestern Medical CenterNCT07878689Written as Tegavivint
- Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung CancerRecruitingPhase 1Ohio State University Comprehensive Cancer CenterNCT04780568Written as Tegavivint
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsRecruitingPhase 1/2Children's Oncology GroupNCT04851119Written as Tegavivint
- Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal CarcinomaRecruitingPhase 1/2HonorHealth Research InstituteNCT07463599Written as Tegavivint
- Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell LymphomaRecruitingPhase 1Lapo AlinariNCT05755087Written as Tegavivint
- Tegavivint for the Treatment of Relapsed or Refractory LeukemiaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT04874480Written as Tegavivint
- Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059CompletedPhase 1Iterion TherapeuticsNCT03459469Written as Tegavivint
Given in every arm · 1 — tegavivint is usual care beside what is tested
Codes
What other systems call tegavivint · ClinicalTrials.gg INT014294
- UNII (FDA) 18AP231HUPTEGAVIVINTOne source FDA
- NCI Thesaurus C155885TegavivintOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 18AP231HUP | TEGAVIVINT | One source FDA |
| NCI Thesaurus | C155885 | Tegavivint | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.